戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 panied by behavioral arrest and inhibited by ethosuximide.
2 e cortex and thalamus that were inhibited by ethosuximide.
3 ice were evaluated by EEG and sensitivity to ethosuximide.
4 gs, phenytoin, phenobarbital, valproate, and ethosuximide.
5 hism on channel physiology in the absence of ethosuximide.
6  on T-type calcium channel responsiveness to ethosuximide.
7 pectively; odds ratio with valproic acid vs. ethosuximide, 1.26; 95% confidence interval [CI], 0.80 t
8 who were randomly assigned to treatment with ethosuximide (156), lamotrigine (149), or valproic acid
9                                              Ethosuximide, a T-type calcium channel blocker, eliminat
10            The results demonstrate that both ethosuximide and the active metabolite of methsuximide,
11                                              Ethosuximide and valproic acid are more effective than l
12  therapy, the freedom-from-failure rates for ethosuximide and valproic acid were similar (53% and 58%
13 d with behavioral arrest, were suppressed by ethosuximide, and were strongest in the cerebral cortex
14 screen revealed that the anti-epileptic drug ethosuximide could restore chemotaxis in dnj-14 ANCL mut
15 e of the clinically used antiepileptic drugs ethosuximide (ED50 = 161 mg/kg), phenobarbital (ED50 = 2
16                  The in vivo P640L variant's ethosuximide effect was confirmed by in vitro electrophy
17                                              Ethosuximide (ETH), an anticonvulsant drug is used for t
18 ferentially blocked the sustained phase, but ethosuximide had no effect.
19 y, and sensitivity to the anti-absence drug, ethosuximide; however, SWD bursts were less frequent and
20 s current was especially sensitive to block (ethosuximide IC(50) = 0.6 mM).
21 was more common with valproic acid than with ethosuximide (in 49% of the children vs. 33%; odds ratio
22                                              Ethosuximide is associated with fewer adverse attentiona
23 safety profile than clinically relevant AEDs ethosuximide, lacosamide, or valproic acid.
24 ildren in a randomized double-blind trial of ethosuximide, lamotrigine, and valproate had short-term
25 ell-known antiepileptic drugs (AEDs) such as ethosuximide, levetiracetam, and lacosamide.
26 ts of well-known antiepileptic drugs such as ethosuximide, levetiracetam, and lacosamide.
27                           This suggests that ethosuximide may have therapeutic potential for ANCL and
28 o normal by either the absence epilepsy drug ethosuximide or a novel T-channel blocker, TTA-P2.
29                                              Ethosuximide's effect on rate of decay of CaV 3.2 was si
30                               Treatment with ethosuximide significantly blocks seizures in both genot
31                               Treatment with ethosuximide significantly blocks seizures in both stg/s
32                                           In ethosuximide subjects, 2 polymorphisms (CACNA1H rs617344
33                         Here, we report that ethosuximide, trimethadione, and 3,3-diethyl-2-pyrrolidi
34 erability, and neuropsychological effects of ethosuximide, valproic acid, and lamotrigine in children
35 c epilepsy syndrome, is usually treated with ethosuximide, valproic acid, or lamotrigine.
36 e rate for lamotrigine (29%; odds ratio with ethosuximide vs. lamotrigine, 2.66; 95% CI, 1.65 to 4.28
37 ult of a spinal cord injury and suggest that ethosuximide will relieve human CPS by restoring normal